

**BIOPHYSICAL GATEKEEPING: A CRITICAL QUALITY ATTRIBUTE (CQA) FRAMEWORK FOR LIPOSOMAL DELIVERY SYSTEMS****Sunil Agarwal, Ranita Roy\*, Argha Chakraborty**

West Bengal Chemical Industries Limited, 145/1, Jessore Rd, Block A, Lake Town, Kolkata,  
West Bengal, 700089, India.

Article Received on 05 June 2026,

Article Revised on 25 June 2026,

Article Published on 01 July 2026,

<https://doi.org/10.5281/zenodo.21067106>

**\*Corresponding Author****Ranita Roy**

West Bengal Chemical Industries  
Limited, 145/1, Jessore Rd, Block A,  
Lake Town, Kolkata, West Bengal  
700089, India.



**How To Cite This Article:** Sunil Agarwal, Ranita Roy\*, Argha Chakraborty. (2026). Biophysical Gatekeeping: A Critical Quality Attribute (CQA) Framework for Liposomal Delivery Systems. World Journal of Pharmacy and Pharmaceutical Sciences, 15(7), 1067–1091. This work is licensed under Creative Commons Attribution 4.0 International license.

**ABSTRACT**

Liposomal encapsulation has redefined the delivery of drugs and nutrients by mimicking natural biological membranes. Despite their potential, transitioning these microscopic vesicles from the laboratory to large-scale industrial production is often hindered by physical inconsistency. This review introduces a structured framework termed "Biophysical Gatekeeping," a protocol that replaces traditional methods with precise "formulation engineering." This approach ensures that every batch meets specific safety and performance standards before moving toward clinical use. Central to this framework is WBCIL's LipoEdge™ technology, an advanced manufacturing platform designed to solve the industrial challenge of vesicle heterogeneity. LipoEdge™ ensures that Critical Quality Attributes (CQAs) are mathematically designed into the liposomal architecture. The process is organized into four

sequential "Gates." First, Vesicle Architecture ensures particles are the correct size and shape. Second, Surface Chemistry validates the electrical charge and protective coatings to prevent clumping in the blood. Third, Compositional Efficiency confirms that at least 80% of the active ingredient is successfully encapsulated. Finally, Biological Validation tests survival through stomach acid and entry into the bloodstream. By following these gates, LipoEdge™ technology reliably bypasses the liver's "first-pass" metabolism, significantly increasing the amount of nutraceuticals/pharmaceuticals that reach the body. This systematic protocol ensures that liposomes are not just simple transport vehicles, but robust, engineered guardians that protect their therapeutic payload until it reaches its destination.

**KEYWORDS:** LipoEdge™ technology, WBCIL, liposome, CQA.

## 1. INTRODUCTION


### 1.1 The Renaissance of Liposomal Delivery

With the discovery of liposomes in 1965 by Alec Bangham.<sup>[1]</sup>, the definition of biomolecule/drug carrier has changed drastically. These microscopic spherical vesicles, composed of one or more phospholipid bilayers that mimic the composition of our biological membranes, have revolutionised modern treatment by providing targeted treatment, efficient delivery and enhanced bioavailability with reduced adverse effects. The primary advantage of liposomes lies in their amphiphilic nature, which enables the simultaneous encapsulation of hydrophilic molecules within the internal aqueous core and lipophilic agents within the hydrophobic lipid bilayer.<sup>[1]</sup>

In the modern pharmaceutical, nutraceutical and cosmeceutical landscape, liposomal technology is increasingly utilized to overcome the inherent limitations of poor aqueous solubility, short biological half-lives, and high metabolic instability. For example, R alpha-lipoic acid (RLA), a potent antioxidant that undergoes extensive degradation in highly acidic environments and at heat, often results in the formation of water-insoluble polymers that significantly reduce its oral absorption.<sup>[2]</sup> Fullerene C60 (C60) has a rigid carbon nanostructure with excellent antioxidant potential, but is naturally insoluble in water, requiring complexation to become biologically applicable.<sup>[3]</sup> Melatonin, secreted by our pineal gland, is a popular over-the-counter drug essential for maintaining circadian rhythm, but it suffers from a low oral bioavailability of approximately 15% due to extensive first-pass hepatic metabolism.<sup>[4]</sup> Thus, liposomes are not simple transport vehicles but enhance biological efficacy by providing a biophysical "gatekeeping".

Liposomes protect the encapsulated active from physiological degradation in the acidic environment of the stomach and rapid clearance from the plasma.<sup>[5]</sup> This protective sequestration ensures that active ingredients reach the therapeutic threshold required for effective physiological function through sustained delivery, without overwhelming the system with a sudden influx of molecules. Furthermore, liposomal encapsulation can modulate a compound's permeability and safety profile. In topical applications, liposomes can facilitate epidermis penetration while preventing deeper dermal entry, thereby avoiding systemic circulation and potential toxicity.<sup>[6]</sup> In oral delivery, they can facilitate absorption through the lymphatic pathway, effectively bypassing first-pass hepatic metabolism and increasing

systemic exposure.<sup>[7]</sup> By modulating the structure of the liposome, we can achieve targeted delivery.



**Figure 1: Diagrammatic representation of a liposome, surface engineering strategies and types of liposomes.**

This review establishes a framework for identifying Critical Quality Attributes (CQAs), such as particle size and charge, encapsulation efficiency, membrane stability, and dermal permeation, that define the success of liposomal systems in navigating complex biological barriers.

### 1.2 The Industrial Challenge: Vesicle Homogeneity and Scale-Up

While liposomes show great clinical promise, their translation from a laboratory synthesis to industrial-scale manufacturing is often hindered by heterogeneity. Inconsistency in vesicle diameter, surface charge, encapsulation efficiency and membrane stability can lead to inconsistent drug release profiles, compromised chemical stability, and unpredictable pharmacokinetics.

West Bengal Chemical Industries Limited (WBCIL) realizes that maintaining batch-to-batch consistency in CQAs is the single greatest challenge in the development of next-generation liposomal delivery systems. To address this, WBCIL implements a framework termed "Biophysical Gatekeeping." Under this protocol, quantifiable Critical Quality Attributes (CQAs) serve as mandatory predictors of liposomes biological performance. This transition from "formulation art" to "formulation engineering-LipoEdge™" ensures that therapeutic outcomes such as bypassing hepatic first-pass metabolism for nutraceuticals and

pharmaceuticals and achieving high dermal/epidermal delivery are mathematically designed into the liposomal architecture.

## 2. The First Gate: Vesicle Architecture and Dimensions

The first "gate" a formulation must pass is the verification of its physical dimensions and structural integrity, as these parameters dictate the route of absorption and biodistribution.

### 2.1 Hydrodynamic Diameter and Polydispersity (PDI)

Particle size and Particle size distribution or polydispersity index (PDI) are the two most fundamentally recognized critical physical quality attributes of a liposomal system, as they determine the formulation's colloidal stability, encapsulation efficiency, long-term stability, biodistribution, biological performance and industrial scalability.<sup>[8]</sup> The average hydrodynamic diameter directly influences the surface-to-volume ratio, which in turn dictates the kinetics of drug release and the extent of interaction with biological membranes. Dynamic Light Scattering (DLS), also known as Photon Correlation Spectroscopy (PCS), remains the primary analytical methodology for characterizing these submicron dispersed systems.

#### 2.1.1. Impact of Composition on Vesicular Dimensions

The final size of a liposome is not merely a result of processing (such as sonication or microfluidization) but is intrinsically linked to its biochemical composition.

- **Active Ingredient Loading:** The integration of hydrophilic compounds can cause significant size expansion. For example, loading liposomes with zinc sulfate has been shown to increase mean particle diameter due to the incorporation of the salt within the phospholipid bilayers.<sup>[9]</sup> The size of the liposome determines its half-life.<sup>[10]</sup>
- **Phospholipid Saturation:** The choice of lipid tail plays a structural role. Substituting unsaturated soybean phospholipids (SPC) with hydrogenated soybean phospholipids (HSPC) increases vesicle size.<sup>[11]</sup> This is attributed to increased van der Waals interactions between saturated chains, which reduces membrane fluidity and leads to larger diameters as the rigid membranes resist the high curvature required for smaller vesicles.
- **Stabilizing Coatings:** Surface modifications, such as the addition of a maltodextrin, pectin coating, further increase the overall vesicular thickness and measured diameter.

### 2.1.2. Stability and Biological Gatekeeping

From a "gatekeeping" perspective, maintaining a consistent size and PDI are essential for ensuring that the liposomes can bypass specific physiological barriers.

- **Intestinal Absorption:** The size of liposomes is modulated based on their application. The size determines its EE, half-life and biodistribution. The size of a liposome can vary from 0.025  $\mu\text{m}$  to 2.5  $\mu\text{m}$ , and based on its lamellarity and size, it is broadly categorised into two groups: (1) multilamellar vesicles (MLV) and (2) unilamellar vesicles. Unilamellar vesicles is further classified into-(1) large unilamellar vesicles (LUV) and (2) small unilamellar vesicles (SUV).<sup>[12]</sup> The absorption of liposomes by intestinal cells is strictly size-dependent. Research indicates that the bioavailability of smaller liposomes can be up to 12 times higher than that of their larger counterparts.<sup>[5]</sup>

- **Stability Marker:** A significant increase in particle size during storage is a primary indicator of physical instability, often signalling vesicle aggregation or fusion. Conversely, a loss of size or a reduction in turbidity may indicate the breakdown of the architectural gate and the formation of lipid fragments.<sup>[13]</sup> Under both conditions, significant amount of encapsulated active is lost.

- **Industrial Benchmarks:** In pharmaceutical science, a  $\text{PDI} < 0.5$  is generally considered the benchmark for a sufficiently homogeneous/ monodisperse population. For specialized drug delivery, a  $\text{PDI} \leq 0.1$  is sought, as it indicates a highly monodispersed system. Conversely, values exceeding 0.7 indicate highly polydispersed systems with significant heterogeneity.<sup>[8]</sup>

- **Uniform Biodistribution:** Low PDI ensures better biodistribution and greater cellular uptake.  $\text{PDI} > 0.7$  increases heterogeneity in size, which can lead to potential tissue accumulation. High PDI results in liposomal sedimentation and aggregation that can significantly alter cellular uptake, toxicity and diffusion. Thus, it is essential to minimize the sedimentation, and aggregation rates of liposomal formulations.<sup>[14]</sup>

### 2.1.3. The Role of Dynamic Light Scattering (DLS)

DLS operates on the principle of analyzing the time-dependent fluctuations in scattered light intensity caused by the perpetual random movement of particles, known as Brownian Motion.<sup>[15]</sup>

- **Diffusion Mechanics:** Smaller particles move more rapidly, causing faster intensity fluctuations, while larger particles move more slowly, resulting in slower fluctuations.<sup>[15]</sup>

- **The Stokes-Einstein Equation:** The DLS instrument calculates the average hydrodynamic diameter ( $x$ ) using the Stokes-Einstein equation:

$$X = kT/3\pi D$$

Where  $x$  is the hydrodynamic diameter,  $k$  is the Boltzmann constant,  $T$  is the absolute temperature,  $\pi$  is the viscosity of the dispersing medium, and  $D$  is the translational diffusion coefficient.<sup>[15]</sup>

According to USP <430>, the relative standard deviation of at least five repeated measurements must not exceed 2% to ensure instrument qualification.<sup>[16]</sup>

## 2.2 Morphology and Structural Integrity

Vesicle dimensions must be supported by structural verification to distinguish between unilamellar and multilamellar vesicles.

- **Visualization:** Techniques such as Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM) and Cryo-TEM are employed to validate that the spherical structure of liposome remains intact even after surface modifications or drug loading.

- **Load Localization:** Cryo-TEM can take high-resolution images of the liposomes and location of the active unlike SEM/TEM.<sup>[17]</sup> In one such study cryo-TEM successfully visualized mefloquine crystals located within the liposomal aqueous core, confirming that the drug was not merely associated with the surface.<sup>[18]</sup> Thus, serving as one of the definitive tests for a successful liposomal encapsulation process.

- Scanning Electron Microscopy (SEM) and Field Emission SEM (FE-SEM) are utilized to confirm the spherical nature of vesicles and identify potential heterogeneity, such as the encapsulation of multiple vesicles within a single matrix.

Thermodynamic instability can lead to either vesicle fusion, where smaller liposomes merge to form larger, irregular structures or the unsaturated phospholipids undergo extensive lipid peroxidation leading to membrane breakdown and leakage. High resolution imaging using SEM & TEM provides direct evidence of liposomal structural integrity.

### 3. The Second Gate: Surface Chemistry and Core Stability

#### 3.1 Zeta Potential: The Electrostatic Gate

Zeta potential is a critical quality attribute (CQA) that measures the electrical potential at the "slipping plane"-the boundary between the stationary fluid layer attached to the dispersed particle and the bulk solvent. It serves as a primary "gatekeeper" for both colloidal stability and physiological safety, dictating how liposomes interact with their environment and with each other.<sup>[20]</sup> The magnitude of the zeta potential provides a quantitative assessment of the electrostatic repulsion between particles in a suspension.

- **The Stability Benchmark:** In pharmaceutical engineering, zeta potential values exceeding +30 mV or falling below -30 mV are considered the gold standard for achieving long-term stability.<sup>[20]</sup>
- **Preventing Structural Failure:** These high absolute values ensure that the repulsive forces between vesicles are strong enough to overcome the attractive van der Waals forces. When the zeta potential approaches zero, the "electrostatic gate" fails, leading to vesicle aggregation, fusion into larger structures, or rapid sedimentation.
- **Technological Innovations:** West Bengal Chemical Industries Limited (WBCIL) utilize stable phospholipids to ensure next-generation liposomal APIs maintain a zeta potential of <-30 mV, guaranteeing high stability and resistance to aggregation.

##### 3.1.1. Safety Correlation and Hemocompatibility

The surface charge of a liposome is not only a marker of stability but also a determinant of its safety profile within the systemic circulation.

- **Hemagglutination Risks:** In therapeutics, formulations with low absolute zeta potential values are prone to facilitating undesirable interactions with blood components. Specifically, a strong positive surface charge can cause hemagglutination, in which red blood cells (RBCs) clump together, potentially leading to vascular complications.<sup>[20,21]</sup>
- **Maintaining the Blood Barrier:** High absolute negative charge values are essential to minimize non-specific interactions with plasma proteins and RBCs. This ensures that the liposomes remain "stealthy" and do not disrupt the integrity of the blood barrier or become prematurely cleared by the immune system.<sup>[21]</sup>

- **Cellular uptake:** It has been observed that liposomes with a strong negative surface charge interact less with the mucus layer, preventing their aggregation on the cell surface, thus enhancing cellular uptake.<sup>[22,23]</sup>

### 3.1.2. pH Dependency and Environmental Sensitivity

Zeta potential is inherently dynamic and highly sensitive to the chemical composition of the surrounding medium.

- **Charge Reversal:** The surface charge of liposomal phospholipids typically shifts in response to pH fluctuations. At low pH (acidic conditions), protonation of functional groups can increase the zeta potential. Conversely, in high pH (alkaline) conditions, deprotonation leads to a more negative charge.<sup>[19]</sup>
- **Impact on Stability:** This dependency is particularly relevant for oral delivery, where liposomes encounter the extreme acidity of the stomach (pH 1.2) followed by the near-neutral or slightly alkaline environment of the small intestine (pH 6.8–7.0). These shifts can trigger membrane instability or change the "mucus-binding" ability of the vesicles, affecting overall bioavailability.

## 3.2 Surface Engineering and Steric Shielding

The biological efficacy of a liposomal system depends highly on the surface structural integrity, which serves as a protective barrier against enzymatic hydrolysis, oxidative stress, and pH-driven degradation. Surface coating with stabilizing components like cholesterol, hydrogenated phospholipids, and polymeric coatings creates a "steric shield" that modulates membrane permeability and prevents premature cargo release. The success of this engineering is validated through advanced biophysical characterization techniques, including Fourier Transform Infrared (FTIR) spectroscopy, Thermogravimetric Analysis (TGA), and Differential Scanning Calorimetry (DSC).

### 3.2.1. Gastric Stability and Chemical Vulnerability

The stomach serves as the first major biological hurdle for oral delivery systems. Sensitive actives like vitamin C, ALA, glutathione, and curcumin undergo bio-oxidation in the acidic gastric environment, resulting in a sharp drop in their bioavailability. It has been observed that liposomal encapsulation provides a robust physical barrier by isolating the active ingredients from the acidic lumen.<sup>[1]</sup> Studies have demonstrated that such liposomal systems

can preserve 100% of the active ingredient under simulated gastric conditions, where the free form would otherwise be degraded.

### 3.2.1.1. Structural Reinforcement and the Steric Barrier

To maintain liposome integrity throughout the gastrointestinal tract, specific components are incorporated into the bilayer to modulate membrane fluidity and permeability. For instance:

- **Cholesterol Integration:** Cholesterol is a ubiquitous stabilizing agent in traditional liposome preparation. It functions by filling interspaces in the hydrophobic region of the membrane, thereby modulating membrane permeability, fluidity, and improves the bilayer stability in the presence of biological fluids such as plasma and blood.<sup>[10]</sup>

- **Hydrogenated Phospholipids (HSPC):** Substituting unsaturated phospholipids with saturated or hydrogenated ones, such as 1,2-distearoyl-sn-glycero-3-phosphocholine (HSPC), significantly enhances the structural stability of liposomes. Hydrogenated phospholipids exhibit higher phase transition temperatures ( $T_m$ ), forming rigid gel-phase membranes at or below human body temperature.<sup>[11]</sup>

### 3.2.1.2. Specialized Coatings and Polymeric Shielding

Beyond the primary lipid components, surface modification through biopolymers offers an additional layer of protection.

- **Maltodextrin Stabilization:** Formulating liposomes with maltodextrin as a stabilizing agent during optimized spray-drying has been shown to enhance structural integrity.<sup>[9]</sup> This coating serves as a supplementary layer that increases vesicular thickness and protects the phospholipids from oxidative degradation and leakage during storage and digestion.

- **Chitosan: Mucoadhesive and pH-Responsive Coating:** Chitosan, a cationic biopolymer, is utilized to impart positive surface charges and mucoadhesive properties to liposomes.<sup>[24]</sup> It interacts with negatively charged phospholipid headgroups, shifting the zeta potential toward positive values, thereby enhancing stability via electrostatic repulsion. The primary benefit of chitosan is its ability to adhere to mucosal surfaces, such as the buccal or intestinal mucosa, thereby prolonging liposome residence time at the absorption site.

- **Pectin and Natural Polysaccharides:** It offers unique rheological and protective benefits, particularly for oral delivery. Polysaccharide coatings can maintain structural stability under the extremely low pH of gastric fluid (pH 2.0), protecting the lipid core from

acid-induced hydrolysis.<sup>[25]</sup> High-methoxyl pectins can modulate the apparent viscosity of the formulation, which influences the release kinetics and potentially inhibits the premature "burst" release in the small intestine.

- **PEGylation:** Polyethylene glycol (PEG) is the gold standard for surface engineering to achieve "stealth" characteristics.<sup>[26]</sup> PEG creates a dense, hydrophilic brush layer that prevents the adsorption of plasma proteins (opsonins) to the liposome surface. This steric barrier reduces recognition and clearance by the mononuclear phagocyte system, significantly increasing the half-life of the formulation in the systemic circulation.

### 3.3 Encapsulation Efficiency (EE%) and Core Optimization

The therapeutic potency of a liposomal system is fundamentally governed by its ability to sequester and retain the active pharmaceutical ingredient (API) within its aqueous core or lipid bilayer. Achieving high drug-to-lipid ratios while maintaining structural stability & integrity is a primary requisite in formulation science that needs to be fulfilled.

#### WBCIL Standards for Commercial Viability

At **West Bengal Chemical Industries Limited (WBCIL)**, Encapsulation Efficiency (EE%) serves as a non-negotiable benchmark for quality.

- **Efficiency Benchmarks:** For a formulation to be considered commercially viable and clinically effective, WBCIL mandates an EE% of  $\geq 80\%$
- **Quality Metrics:** This high threshold ensures that a minimal amount of the active ingredient remains "free" in the external medium, which reduces the risk of premature degradation or undesirable side effects often associated with unencapsulated drugs.
- **Stability Correlations:** High encapsulation efficiency is often a surrogate marker to understand the liposomal integrity; any significant reduction in EE% during storage typically signals lipid oxidation, vesicle aggregation, or membrane leakage.

#### 3.3.2 Drug Loading Capacity (LC) and Drug-to-Lipid Ratios

Loading capacity (LC) defines the weight of the entrapped drug per unit weight of the lipid matrix, serving as a critical indicator of the system's efficiency.

- **Loading Parameters:** LC is calculated by assessing the mass of lipids that effectively contains the encapsulated drug. In advanced liposomal formulations by WBCIL's

LipoEdge™ technology, such as iron loaded liposomes, LC values ~71%. Higher LC ensures lower therapeutic dose.

- **Drug-to-Lipid Ratio:** This ratio is a primary determinant of dose density. High-performance systems aim for optimized mass ratios; for example, curcumin liposomes have been successfully stabilized using a soybean phospholipid, cholesterol, and curcumin ratio of 40:8:1 (w/w/w).<sup>[27]</sup>

### 3.4. Molecular Interaction Analysis via FTIR

FTIR spectroscopy is a non-destructive analytical tool<sup>[28]</sup> used to identify functional groups and probe molecular interactions within the liposomal architecture.

- **Phospholipid Coordination:** Shifts in characteristic peaks reveal the binding patterns of encapsulated actives. For instance, in zinc-loaded liposomes, shifts in P=O stretching (~1247 cm<sup>-1</sup>) and water coordination peaks (~460 cm<sup>-1</sup>) confirm specific Zn<sup>2+</sup> phospholipid coordination within the bilayer.<sup>[9]</sup>
- **Hydrogen Bonding:** Changes in the stretching vibration peaks of C-H bonds (2800-3000 cm<sup>-1</sup>) and carbonyl groups (C=O, ~1732 cm<sup>-1</sup>) signal the formation of H-bonds between cholesterol, the active ingredient, and the lipid headgroups.<sup>[9]</sup>
- **Chain Saturation Effects:** As hydrogenated phospholipid (HSPC) content increases, stretching vibration peaks for C-H bonds shift to lower wavenumbers (e.g., from 2926 to 2917 cm<sup>-1</sup>), indicating denser lipid chain packing due to increased van der Waals Interactions.<sup>[27]</sup>

### 3.5. Thermal Stability and Decomposition via TGA

TGA provides quantitative data on the thermal decomposition patterns and structural integrity of the formulation by measuring weight loss as a function of temperature.

- **Encapsulation Signatures:** Active-loaded liposomes exhibit unique thermal behavior distinct from free active and pure lecithin.<sup>[9]</sup> For example, while pure zinc sulfate heptahydrate undergoes rapid initial weight loss (~30%) up to 100 °C due to water loss, encapsulated versions show more gradual, controlled water loss.
- **Bilayer Protection:** The liposomal matrix improves the thermal stability of its components, showing enhanced resistance to decomposition between compared to pure

phospholipids.<sup>[9]</sup> This confirms that liposomal encapsulation successfully shields the organic core from rapid thermal degradation.

### 3.2.3. Phase Behavior and Molecular Ordering via DSC

Differential Scanning Calorimetry (DSC) is a cornerstone analytical technique in the biophysical characterization of liposomal systems. It provides a quantitative thermodynamic profile that serves as a direct indicator of membrane integrity, drug-lipid interactions, and long-term stability.<sup>[29]</sup>

#### Relevance of DSC Studies

The primary relevance of DSC lies in its ability to monitor the thermotropic phase behavior of the lipid bilayer. Liposomes transition between different physical states based on temperature most notably from a rigid, ordered gel phase ( $L\beta$ ) to a fluid, disordered liquid-crystalline phase ( $L\alpha$ ).<sup>[30]</sup>

- **Determining Phase Transition Temperature ( $T_m$ ):** DSC accurately identifies the  $T_m$  (melting point) where this structural transition occurs. For instance, non-hydrogenated soybean phospholipids (SPC) have a  $T_m$  below  $0^\circ\text{C}$ , whereas hydrogenated versions (HSPC) exhibit much higher transitions ( $> 55^\circ\text{C}$ ).<sup>[31]</sup>
- **Quantifying Enthalpy ( $\Delta H$ ):** The area under the endothermic peak represents the enthalpy, which correlates with the energy required to disrupt the van der Waals interactions between lipid tails. Higher  $\Delta H$  values typically indicate a more ordered and cohesive membrane structure.

#### Why DSC is Essential for Liposomal Performance

DSC is an indispensable "gatekeeping" tool for several reasons:

1. **Predicting Drug Retention and Leakage:** A formulation whose  $T_m$  is close to or below physiological temperature ( $37^\circ\text{C}$ ) may become overly fluid in the body, leading to premature cargo release.<sup>[32]</sup> DSC helps in designing bilayers that remain in a stable, less permeable state during circulation.
2. **Assessing Formulation Homogeneity:** The shape and width of the DSC peaks provide a signature of molecular ordering.<sup>[29]</sup> Sharp, well-defined peaks indicate a uniform lipid environment, while broad or multiple peaks signal phase coexistence, which can be strategically used to optimize controlled release kinetics.

**3. Verifying Molecular Interactions:** The shift or disappearance of a lipid transition peak upon the addition of a drug or cholesterol confirms successful integration into the bilayer.<sup>[29]</sup> For example, high cholesterol concentrations can abolish the sharp gel-to-liquid transition, creating a stable state that enhances the retention of actives such as curcumin or melatonin.

**4. Stability Monitoring:** Changes in the thermogram over time, such as shifts in  $T_m$  or changes in enthalpy, can serve as an early warning for lipid oxidation or physical degradation, ensuring that the formulation meets the rigorous quality standards required for clinical translation.

#### 4. The Third Gate: In Vitro Biological Validation

##### 4.1. Gastrointestinal Stability, Bioavailability, and Triggered Release

The final phase of biological gatekeeping evaluates the liposome's performance in physiological simulations. This stage ensures that the delivery system can survive hostile environmental transitions while maintaining the functional efficacy and bioavailability of its therapeutic payload.

##### 4.1.1. Survival in the Gastrointestinal (GI) Tract

Oral liposomal formulations must withstand sequential exposure to varied chemical and enzymatic stresses.

- **Gastric Resilience (SGF):** Simulated Gastric Fluid (SGF) presents an extreme challenge with a pH of 1.2–3.0 and the presence of pepsin. In contrast to free actives that degrade by 75% within an hour in the stomach, liposomes maintain over 80% structural integrity and limit API release to below 20% under simulated gastric conditions.<sup>[33]</sup>
- **Intestinal Transition (SIF):** In Simulated Intestinal Fluid (SIF, pH 6.8–7.0), the liposomes encounter bile salts and pancreatic lipases. Bile salts can emulsify the bilayer into micelles, while lipases chemically hydrolyze phospholipids, modulating the release profile of liposomes.<sup>[33]</sup>
- **Sustained Release Profiling:** Effective gatekeeping is evidenced by a sustained-release profile reaching approximately 95% cumulative release over 12–24 hours, compared to the rapid dissolution (complete release in 20 minutes) and/or degradation of free drug solutions.<sup>[33]</sup>

#### 4.1.2. In Vitro Bioavailability and Caco-2 Cell Permeation

Beyond physical stability, the "biological gate" requires evidence of successful uptake. The **Caco-2 cell line**, derived from human colon adenocarcinoma, is the industrial standard for simulating the intestinal epithelial barrier.<sup>[34]</sup>

- **Cellular Uptake and Transport:** Liposomes enhance bioavailability by protecting actives from extensive first-pass hepatic metabolism. Caco-2 models allow measurement of the Apparent Permeability Coefficient (Papp), which quantifies the extent to which vesicles penetrate the intestinal epithelial cells.<sup>[35]</sup>
- **Mechanism of Absorption:** Liposomes interact with enterocytes via clathrin/caveolae-mediated endocytosis. Once inside the cell, they can interact with chylomicrons to enter the lymphatic system (lacteals), which selectively transports lipophilic compounds to the general circulation without passing through the liver.

#### 4.1.3. In Vitro Functional Efficacy Assays

The therapeutic efficacy of the cargo must be preserved post-digestion to pass the functional gate.

##### (i) Antioxidant Capacity Assays (DPPH and ABTS)

These assays evaluate the cumulative ability of the liposomal formulation to provide hydrogen atoms or electrons to neutralize stable free radicals.

- **DPPH Assay:** This spectrophotometric method utilizes the stable 2, 2-diphenyl-1-picrylhydrazyl radical. In the presence of ROS, it fluoresces green.<sup>[36]</sup> Its fluorescence is directly proportional to the ROS produced.
- **ABTS Assay:** Often used to verify the scavenging activity of hydrophilic and lipophilic actives, this assay establishes dose-dependent inhibition curves to ensure the encapsulation process has not compromised the active's reductive potential.<sup>[37]</sup>
- Biological gatekeeping requires the liposomal system to exhibit antioxidant power comparable to, or exceeding, standard controls like Vitamin C or Quercetin.

##### (ii) Oxidative Stress Mitigation and Lipid Peroxidation

The **TBARS (Thiobarbituric Acid Reactive Substances) assay** is the primary diagnostic tool for measuring the inhibition of lipid peroxidation.<sup>[38]</sup> This assay assesses the formulation's ability to prevent the oxidative degradation of lipids into malondialdehyde

(MDA). It is critical for evaluating how well the liposomal carrier protects its own phospholipid bilayer and external biological membranes from damage during systemic circulation and long-term storage. Highly optimized liposomal formulations, such as those utilizing hydrogenated soybean phospholipids (HSPC), show negligible changes in TBARS values over extended periods, indicating superior resistance to oxidative stress.<sup>[39]</sup>

### (iii) Hemocompatibility and Osmotic Fragility

Safety assessment requires rigorous testing of the interaction between liposomes and hematological components.

- **Hemocompatibility and Agglutination:** Hemocompatibility is a non-negotiable biological gatekeeper that ensures liposomal delivery systems are not lethal to cellular blood components upon entering systemic circulation.<sup>[40]</sup> This safety validation guarantees that the nanocarriers maintain physiological homeostasis without triggering adverse hematological events. For a formulation to be blood-compatible, high absolute zeta potential values (typically  $<-30$  mV) are required to provide sufficient electrostatic repulsion.<sup>[41]</sup> This strong negative charge prevents vesicles from facilitating hemagglutination, a dangerous clumping of red blood cells that can lead to vascular occlusion or systemic toxicity. West Bengal Chemical Industries Limited (WBCIL) ensure their liposomal APIs are biocompatible and safe for blood contact resulting in  $<5\%$  death.

- **Osmotic Fragility:** This assay is complementary to the hemocompatibility assay. It ensures that the liposomal vesicles do not cause mechanical rupture of red blood cell membranes under varying osmotic pressures, which is essential for ensuring the safety of blood-contacting therapeutics and intravenous delivery systems.<sup>[42]</sup>

## 5. Fourth Gate: *In vivo* Biological Gatekeeping: Performance in Physiological Contexts Pharmacokinetics and Bioavailability Enhancement

The ultimate biological objective of liposomal engineering is the optimization of a drug's pharmacokinetic (PK) profile. By establishing a protective biophysical gate, liposomes modulate the absorption, distribution, metabolism, and excretion (ADME) of the active ingredient, significantly altering parameters such as the Area Under the Curve (AUC), Maximum Plasma Concentration ( $C_{max}$ ), and the Time to reach  $C_{max}$ - $T_{max}$ .

#### 4.2.2. Pharmacokinetic Metrics in Animal and Clinical Models

The transition from a conventional formulation to a liposomal system result in marked shifts in PK benchmarks, as demonstrated in specialized animal models (e.g., anesthetized rats with mesenteric lymph duct cannulation) and human crossover trials.

- **Enhanced Bioavailability (AUC):** Liposomal encapsulation can increase the total systemic exposure (AUC). For instance, liposomal melatonin has demonstrated an enhancement in bioavailability of up to 40.45% compared to free forms.<sup>[43]</sup> In specialized spray formulations, the AUC can become comparable to intravenous (IV) administration.
- **Optimized Peak Concentrations (C<sub>max</sub>):** Liposomal delivery systems significantly enhance the peak concentration of active ingredients in systemic circulation compared to conventional oral formulations. Clinical assessments of melatonin delivered via liposomal systems have demonstrated that these advanced formulations can increase plasma levels by approximately 2-fold compared to non-liposomal tablets (e.g., C<sub>max</sub> of 2332±95 pg/mL vs. 1151±565 pg/mL).<sup>[43]</sup>
- **Rapid Onset (T<sub>max</sub>):** T<sub>max</sub> is the time taken to reach the maximum concentration. Clinical evaluations of oral liposomal vitamin C vs. conventional forms often show a T<sub>max</sub> that is identical or even slightly delayed compared to non-liposomal versions (e.g., T<sub>max</sub> of 4 hours for both treatments), even though the liposomal version achieves a significantly higher C<sub>max</sub> and AUC.<sup>[44]</sup> In case of liposomal melatonin, immediate-release oral capsules reach peak levels in approximately 50 minutes (0.87 h), sustained-release liposomal oral formulations may have a T<sub>max</sub> of 1.26 hours or longer.<sup>[45]</sup>

For many oral liposomal APIs, a rapid T<sub>max</sub> is actually avoided in favor of longer plasma retention and a steady therapeutic threshold, which reduces dosing frequency and minimizes side effects.

- **Extended Half-Life (t<sub>1/2</sub>):** Liposomes provide a sustained-release profile, protecting the API from rapid plasma clearance.<sup>[46]</sup> This ensures longer plasma retention and reduces the required frequency of dosing.

#### 4.2.3. Modeling Selectivity and Affinity

Standard animal protocols, such as mass balance experiments in rat models, probe the selectivity of these pathways. The efficacy of lymphatic transport is often dictated by the

partition coefficient (Log P) and the drug's affinity for chylomicrons versus plasma proteins.<sup>[47]</sup> Liposomal delivery systems are critical for overcoming this lipophilicity requirement, serving as engineered vehicles that transport hydrophilic molecules into the lymphatic system. In the case of lipophilic molecules, liposomes prevent precipitation that often occurs when free lipophilic drugs encounter the aqueous environment of the gastrointestinal lumen.<sup>[48]</sup> Naturally lipophilic drugs often have a high affinity for plasma proteins or red blood cells (RBCs).<sup>[49]</sup>, and liposomes facilitate the transfer of these drugs/actives into nascent chylomicrons within the enterocytes. These chylomicron-associated drugs are then secreted into the lacteals, effectively bypassing first-pass hepatic metabolism. Thus, significantly increasing the core parameters such as the AUC and C<sub>max</sub>.

## 6. WBCIL Perspective: Implementing the Biophysical Gatekeeping Framework

The translation of liposomal systems from laboratory innovation to large-scale pharmaceutical production is fundamentally a challenge of consistency. West Bengal Chemical Industries Limited (WBCIL) addresses this challenge through the rigorous implementation of the "Biophysical Gatekeeping" framework-a multi-tiered validation protocol where quantifiable Critical Quality Attributes (CQAs) serve as the mandatory predictors of biological performance of LipoEdge™ liposomes.

### Gate I: Architectural Verification

Every batch at WBCIL must first pass stringent physical dimension checks. Utilizing Dynamic Light Scattering (DLS) and following USP <430> guidelines, formulations are analyzed to ensure a Polydispersity Index (PDI) of <0.5, signaling the high homogeneity required for predictable release. Structural integrity is further verified through high-resolution imaging (SEM, TEM), confirming that vesicles are truly spherical and that active ingredients are properly localized within the core rather than merely surface-associated.

### Gate II: Thermodynamic and Surface Chemistry Validation

WBCIL recognizes that the "electrostatic gate" is vital for stability. Formulations are engineered to maintain a zeta potential of <-30 mV, providing the repulsion necessary to prevent vesicle fusion and hemagglutination in systemic circulation. Furthermore, Differential Scanning Calorimetry (DSC) and FTIR are employed to verify molecular ordering.


### Gate III: Compositional Efficiency and Core Optimization

Industrial viability depends on sequestration efficiency. WBCIL mandates an Encapsulation Efficiency (EE%) of  $\geq 80\%$  as a non-negotiable benchmark. This is complemented by optimizing drug-to-lipid ratios and Loading Capacity (LC).

### Gate IV: Biological Validation and Pharmacokinetic Design

The final gate involves simulating physiological performance. WBCIL formulations are tested for Gastric Resilience (SGF), where liposomes must maintain  $>80\%$  structural integrity. Subsequent Caco-2 cell permeation studies and in vivo pharmacokinetic modelling confirm the successful bypass of first-pass hepatic metabolism via the lymphatic pathway. This systematic approach ensures that products like liposomal vitamin C achieve a 2-4 fold increase in  $C_{max}$  and bioavailability compared to free forms.

Through this four-gate framework, WBCIL ensures that every liposomal delivery system is mathematically designed to meet the therapeutic threshold, providing safer, more effective, and highly stable treatments for pediatric, geriatric, and clinical populations.



**Figure 2: Diagrammatic representation of the evaluation of liposomal formulation.**

## 7. CONCLUSION

The industrial and clinical success of liposomal delivery systems is no longer a matter of serendipitous discovery but a rigorous discipline of formulation engineering. As outlined in this review, the "Biophysical Gatekeeping" framework provides a definitive roadmap for navigating the multifaceted barriers of the human body. By transforming qualitative "art" into

quantifiable Critical Quality Attributes (CQAs), manufacturers can ensure that every vesicle serves as an active guardian of its therapeutic payload.

The integration of Gate I (Architectural Verification) and Gate II (Thermodynamic and Surface Chemistry) ensures that the physical foundations-size, homogeneity, and membrane rigidity are optimized to prevent premature leakage and provide colloidal stability. The transition to Gate III (Compositional Efficiency) guarantees that sequestration metrics, such as a non-negotiable EE% of  $\geq 80\%$ , meet industrial standards for commercial and clinical viability. Finally, Gate IV (Biological Validation) confirms that these engineered systems translate into superior pharmacokinetic outcomes, such as the successful bypass of first-pass hepatic metabolism via the lymphatic pathway and a 2-to-4-fold increase in C<sub>max</sub> and bioavailability.

This systematic approach, exemplified by the standards implemented at West Bengal Chemical Industries Limited (WBCIL), represents the next frontier in drug delivery. By strictly adhering to these four gates, the pharmaceutical and nutraceutical industries can reliably produce highly stable, targeted, and effective liposomal products such as iron, vitamin C, R-alpha-lipoic acid etc that address the unique physiological needs of pediatric, geriatric, and clinical populations worldwide.

**Conflict of Interest Statement:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Source of Funding:** None.

**Author's Contribution:** All authors contributed equally in writing the draft, conceptualisation, review & editing, investigation and research. Mr Sunil Agarwal has also provided guidance and supervised the entire work.

## ACKNOWLEDGEMENT

We are thankful to the Honourable Managing Director of West Bengal Chemical Industries Limited, Mr Sunil Agarwal, for granting us the opportunity to write this review article.

## REFERENCES

1. Bozzuto, G., & Molinari, A. Liposomes as nanomedical devices. *International journal of nanomedicine*, 2015; 10: 975–999. <https://doi.org/10.2147/IJN.S68861>
2. Ikuta, N., Sugiyama, H., Shimosegawa, H., Nakane, R., Ishida, Y., Uekaji, Y., Nakata, D., Pallauf, K., Rimbach, G., Terao, K., & Matsugo, S. Analysis of the enhanced stability of r(+)-alpha lipoic Acid by the complex formation with cyclodextrins. *International journal of molecular sciences*, 2013; 14(2): 3639–3655. <https://doi.org/10.3390/ijms14023639>
3. Prylutskyy, Y. I., Vereshchaka, I. V., Maznychenko, A. V., Bulgakova, N. V., Gonchar, O. O., Kyzyma, O. A., Ritter, U., Scharff, P., Tomiak, T., Nozdrenko, D. M., Mishchenko, I. V., & Kostyukov, A. I. C<sub>60</sub> fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue. *Journal of nanobiotechnology*, 2017; 15(1): 8. <https://doi.org/10.1186/s12951-016-0246-1>
4. DeMuro, R. L., Nafziger, A. N., Blask, D. E., Menhinick, A. M., & Bertino, J. S., Jr. The absolute bioavailability of oral melatonin. *Journal of clinical pharmacology*, 2000; 40(7): 781–784. <https://doi.org/10.1177/00912700022009422>
5. Liu, P., Chen, G., & Zhang, J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. *Molecules (Basel, Switzerland)*, 2022; 27(4): 1372. <https://doi.org/10.3390/molecules270413>
6. Choudhury, A., Kirti, A., Lenka, S. S., Naser, S. S., Sinha, A., Kumari, S., Kaushik, N. K., Ghosh, A., & Verma, S. K. Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis. *Journal of nanobiotechnology*, 2025; 23(1): 576. <https://doi.org/10.1186/s12951-025-03660-z>
7. Ahn, H., & Park, J. H. Liposomal delivery systems for intestinal lymphatic drug transport. *Biomaterials research*, 2016; 20: 36. <https://doi.org/10.1186/s40824-016-0083-1>
8. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. *Pharmaceutics*, 2018; 10(2): 57. <https://doi.org/10.3390/pharmaceutics10020057>
9. Abbassi, M., Nejad Ebrahimi, S., & Rahimi, M. Optimized spray-drying of zinc sulfate-loaded liposomes: physicochemical characterization and in vitro release assessment. *Scientific reports*, 2025; 15(1): 20955. <https://doi.org/10.1038/s41598-025-05948-4>

10. Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. Liposomes: structure, composition, types, and clinical applications. *Heliyon*, 2022; 8(5): e09394. <https://doi.org/10.1016/j.heliyon.2022.e09394>
11. Chen, J., Cheng, D., Li, J., Wang, Y., Guo, J. X., Chen, Z. P., Cai, B. C., & Yang, T. Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. *Drug development and industrial pharmacy*, 2013; 39(2): 197–204. <https://doi.org/10.3109/03639045.2012.668912>
12. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. Liposome: classification, preparation, and applications. *Nanoscale research letters*, 2013; 8(1): 102. <https://doi.org/10.1186/1556-276X-8-102>
13. Yu, J. Y., Chuesiang, P., Shin, G. H., & Park, H. J. Post-Processing Techniques for the Improvement of Liposome Stability. *Pharmaceutics*, 2021; 13(7): 1023. <https://doi.org/10.3390/pharmaceutics13071023>
14. Morla-Folch, J., Ranzenigo, A., Fayad, Z. A., & Teunissen, A. J. P. Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions. *Small (Weinheim an der Bergstrasse, Germany)*, 2024; 20(17): e2307502. <https://doi.org/10.1002/smll.202307502>
15. Falke, S., & Betzel, C. Dynamic Light Scattering (DLS): Principles, Perspectives, Applications to Biological Samples. *Radiation in Bioanalysis: Spectroscopic Techniques and Theoretical Methods*, 2019; 8: 173–193. [https://doi.org/10.1007/978-3-030-28247-9\\_6](https://doi.org/10.1007/978-3-030-28247-9_6)
16. [https://www.usp.org/sites/default/files/usp/document/harmonization/gen-chapter/m11064\\_oct\\_2023.pdf](https://www.usp.org/sites/default/files/usp/document/harmonization/gen-chapter/m11064_oct_2023.pdf)
17. Robson, A. L., Dastoor, P. C., Flynn, J., Palmer, W., Martin, A., Smith, D. W., Woldu, A., & Hua, S. Advantages and Limitations of Current Imaging Techniques for Characterizing Liposome Morphology. *Frontiers in pharmacology*, 2018; 9: 80. <https://doi.org/10.3389/fphar.2018.00080>
18. Tang WL, Tang WH, Chen WC, Diako C, Ross CF, Li SD. Development of a rapidly dissolvable oral pediatric formulation for mefloquine using liposomes. *Molecular Pharmaceutics* [Internet]. 2017 May 1; 14(6): 1969–79. Available from: <https://doi.org/10.1021/acs.molpharmaceut.7b00077>
19. Németh, Z., Csóka, I., Semnani Jazani, R., Sipos, B., Haspel, H., Kozma, G., Kónya, Z., & Dobó, D. G. Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes

- with Charge Imparting Membrane Additives. *Pharmaceutics*, 2022; 14(9): 1798. <https://doi.org/10.3390/pharmaceutics14091798>
20. Andrade, S., Loureiro, J. A., Ramirez, S., Catumbela, C. S. G., Soto, C., Morales, R., & Pereira, M. C. Multi-Dose Intravenous Administration of Neutral and Cationic Liposomes in Mice: An Extensive Toxicity Study. *Pharmaceutics* (Basel, Switzerland), 2022; 15(6): 761. <https://doi.org/10.3390/ph150607>
21. Chonn, A., Cullis, P. R., & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. *Journal of immunology (Baltimore, Md.: 1950)*, 1991; 146(12): 4234–4241.
22. Xia, Y., Fu, S., Ma, Q., Liu, Y., & Zhang, N. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy. *Nano-micro letters*, 2023; 15(1): 145. <https://doi.org/10.1007/s40820-023-01125-2>
23. Li, L. D., Crouzier, T., Sarkar, A., Dunphy, L., Han, J., & Ribbeck, K. Spatial configuration and composition of charge modulates transport into a mucin hydrogel barrier. *Biophysical journal*, 2013; 105(6): 1357–1365. <https://doi.org/10.1016/j.bpj.2013.07.050>
24. Alshraim, M. O., Sangi, S., Harisa, G. I., Alomrani, A. H., Yusuf, O., & Badran, M. M. Chitosan-Coated Flexible Liposomes Magnify the Anticancer Activity and Bioavailability of Docetaxel: Impact on Composition. *Molecules* (Basel, Switzerland), 2019; 24(2): 250. <https://doi.org/10.3390/molecules24020250>
25. Xiao Z, Xiao N, Wu H, Fan Q, Dong Z, Jin Z, et al. Polysaccharide coating synergistically enhances the structural stability and functionality of the cyclodextrin–liposome system for the delivery of essential oils: Mechanistic insights at the molecular level. *Food Research International* [Internet]. 2025 Oct., 28; 222(1): 117756. Available from: <https://doi.org/10.1016/j.foodres.2025.117756>
26. Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Advanced drug delivery reviews*, 2016; 99(A): 28–51. <https://doi.org/10.1016/j.addr.2015.09.012>
27. Tai K, Rappolt M, Mao L, Gao Y, Yuan F. Stability and release performance of curcumin-loaded liposomes with varying content of hydrogenated phospholipids. *Food Chemistry* [Internet]. 2020 May 5; 326: 126973. Available from: <https://doi.org/10.1016/j.foodchem.2020.126973>

28. Barnes, M., Sulé-Suso, J., Millett, J., & Roach, P. Fourier transform infrared spectroscopy as a non-destructive method for analysing herbarium specimens. *Biology letters*, 2023; 19(3): 20220546. <https://doi.org/10.1098/rsbl.2022.0546>
29. Chiu, M. H., & Prenner, E. J. Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions. *Journal of pharmacy & bioallied sciences*, 2011; 3(1): 39–59. <https://doi.org/10.4103/0975-7406.76463>
30. Liu, P., Chen, G., & Zhang, J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. *Molecules (Basel, Switzerland)*, 2022; 27(4): 1372. <https://doi.org/10.3390/molecules27041372>
31. Alavizadeh, S. H., Badiie, A., Golmohammadzadeh, S., & Jaafari, M. R. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. *International journal of pharmaceutics*, 2014; 473(1-2): 326–333. <https://doi.org/10.1016/j.ijpharm.2014.07.020>
32. Sobol, Ž., Chiczewski, R., & Wątróbska-Świetlikowska, D. Advances in Liposomal Drug Delivery: Multidirectional Perspectives on Overcoming Biological Barriers. *Pharmaceutics*, 2025; 17(7): 885. <https://doi.org/10.3390/pharmaceutics17070885>
33. He, H., Lu, Y., Qi, J., Zhao, W., Dong, X., & Wu, W. Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin. *Acta pharmaceutica Sinica. B*, 2018; 8(1): 97–105. <https://doi.org/10.1016/j.apsb.2017.11.007>
34. <https://www.ncbi.nlm.nih.gov/books/NBK500149/>
35. Żmuda, P., Khaidakov, B., Krasowska, M., Czapska, K., Dobkowski, M., Guzowski, J., Kowalczyk, P., Lemke, K., Folwarski, M., Foryś, A., Domian, E., & Postuła, M. Bioavailability of Liposomal Vitamin C in Powder Form: A Randomized, Double-Blind, Cross-Over Trial. *Applied Sciences*, 2024; 14(17): 7718. <https://doi.org/10.3390/app14177718>
36. Protopapa, C., Tsiachlis, I., Kolipaka, S. S., Douroumis, D., Demetzos, C., & Vlachou, M. Formulation and in vitro evaluation of liposomal and self-microemulsifying drug delivery systems for oral delivery of cannabidiol., *Journal of pharmaceutical sciences*, 2026; 115(1): 104053. <https://doi.org/10.1016/j.xphs.2025.104053>
37. Jovanović, A. A., Balanč, B., Volić, M., Pećinar, I., Živković, J., & Šavikin, K. P. Rosehip Extract-Loaded Liposomes for Potential Skin Application: Physicochemical Properties of

- Non- and UV-Irradiated Liposomes. *Plants (Basel, Switzerland)*, 2023; 12(17): 3063. <https://doi.org/10.3390/plants12173063>
38. Aguilar Diaz De Leon, J., & Borges, C. R. Evaluation of Oxidative Stress in Biological Samples Using the Thiobarbituric Acid Reactive Substances Assay. *Journal of visualized experiments: JoVE*, 2020; (159): 10.3791/61122. <https://doi.org/10.3791/61122>
39. Zhu D, Cheng S, Du M. Oxidation-resistant nanoliposomes loaded with osteogenic peptides: Characteristics, stability and bioaccessibility. *Food Research International* [Internet]. 2023 Dec., 20; 177: 113843. Available from: <https://doi.org/10.1016/j.foodres.2023.113843>
40. Markowski, A., Zaremba-Czogalla, M., Jaromin, A., Olczak, E., Zygmunt, A., Etezadi, H., Boyd, B. J., & Gubernator, J. Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterization, and Evaluation. *Pharmaceutics*, 2023; 15(1): 179. <https://doi.org/10.3390/pharmaceutics15010179>
41. Zhang, J., Huang, Y., Shen, W., Zeng, Y., Miao, Y., Feng, N., & Ci, T. Effects of Surface Charge of Inhaled Liposomes on Drug Efficacy and Biocompatibility. *Pharmaceutics*, 2025; 17(3): 329. <https://doi.org/10.3390/pharmaceutics17030329>
42. Alhanaty E, Livne A. Osmotic fragility of liposomes as affected by antihemolytic compounds. *Biochimica Et Biophysica Acta (BBA) - Biomembranes* [Internet]. 1974 Feb., 1; 339(1): 146–55. Available from: [https://doi.org/10.1016/0005-2736\(74\)90340-x](https://doi.org/10.1016/0005-2736(74)90340-x)
43. Agarwal S, Roy R, Chakraborty A, Kar T. Current status and future directions of liposomal melatonin in transmucosal delivery systems: Emphasis on the active ingredient from west Bengal Chemical Industries Limited. *Indian Journal of Pharmacy and Pharmacology* [Internet]. 2026 Feb., 2; 12(4): 206–11. Available from: <https://doi.org/10.18231/j.ijpp.14872.1769489469>
44. Gopi, S., & Balakrishnan, P. Evaluation and clinical comparison studies on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability. *Journal of liposome research*, 2021; 31(4): 356–364. <https://doi.org/10.1080/08982104.2020.1820521>
45. Thanawala, S., Abiraamasundari, R., & Shah, R. Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy

- Adults: A Randomized, Open-Label, Cross-Over Study. *Pharmaceutics*, 2024; 16(10): 1248. <https://doi.org/10.3390/pharmaceutics16101248>
46. Liu, P., Chen, G., & Zhang, J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. *Molecules (Basel, Switzerland)*, 2022; 27(4): 1372. <https://doi.org/10.3390/molecules27041372>
47. Ali Khan, A., Mudassir, J., Mohtar, N., & Darwis, Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. *International journal of nanomedicine*, 2013; 8: 2733–2744. <https://doi.org/10.2147/IJN.S41521>
48. Lee M. K. Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches. *Pharmaceutics*, 2020; 12(3): 264. <https://doi.org/10.3390/pharmaceutics12030264>
49. Lázníček, M., & Láznícková, A. The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. *Journal of pharmaceutical and biomedical analysis*, 1995; 13(7): 823–828. [https://doi.org/10.1016/0731-7085\(95\)01504-e](https://doi.org/10.1016/0731-7085(95)01504-e)